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In humans, about 50 ABC proteins play physiologically important roles. Many ABC proteins are
involved in lipid outward translocation and lipid homeostasis in the body, and defects in their func-
tions cause various diseases. However, the precise mechanisms of substrate transport remain
unclear. In bacteria, several ABC proteins are involved in the transport of lipoproteins and lipopoly-
saccharides from the inner to outer membrane, and their functioning is a prerequisite for survival.
Their functions can be divided into ‘‘ﬂip-ﬂop” and ‘‘projection”. In this review, human ABC proteins
are compared to bacterial proteins to elucidate their mechanisms.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The lipid bilayer is the ideal barrier for life to maintain concen-
trations of solutes in cytosol and selectively segregate biochemical
reactions from the external environment. Because water-soluble
molecules and inorganic ions hardly dissolve in lipid bilayers or
diffuse across them, speciﬁc membrane proteins, transporters
and channels, which transport water-soluble molecules and inor-
ganic ions across lipid bilayers, have evolved and cells have
achieved competency to ingest essential nutrients, excrete meta-
bolic waste products, and regulate intracellular ion concentrations.
By contrast, because hydrophobic molecules readily dissolve in li-
pid bilayers and diffuse across them, they have been considered to
move according to their concentration gradient across membranes
in cells and in the body.
We identiﬁed human MDR1 gene [now called ABCB1 by the
HUGO (Human Gene Organization) Nomenclature Committee]
ampliﬁed and overexpressed in multidrug-resistant carcinoma cell
lines in 1986 [1,2], and showed that it confers multidrug resistance
depending on its own expression. Afterwards, ABCB1 turned out to
code for P-glycoprotein [3], a surface glycoprotein overexpressed
in drug-resistant Chinese hamster ovary cell mutants [4]. MDR1
extrudes a very wide array of structurally dissimilar compounds,chemical Societies. Published by E
ated Cell-Material Sciences
x: +81 75 753 6104.
).all lipophilic or amphiphilic, and ranging in mass from approxi-
mately 300 to 2000 Da, including cytotoxic drugs that act on differ-
ent intracellular targets [5–7]. MDR1 is clinically important
because it not only confers multidrug resistance to cancer cells
but also affects the pharmacokinetics of various drugs [8,9]. This
discovery suggested that lipophilic endogenous compounds, which
have been considered to move according to their concentration
gradient in cells and in the body, could be also actively transported
across membranes in an ATP-dependent manner. Indeed, it was re-
vealed in 1993 that murine ABCB4 (also called MDR2), highly
homologous to MDR1, is involved in phosphatidylcholine (PC)
transport and is indispensable for bile formation [10].
Although several mechanisms have been proposed for substrate
recognition and transport by MDR1 and other ABC proteins [11–
14], they remain to be clariﬁed. Four processes can be predicted
for outward lipid transport across membranes, as seeing in Fig. 1.
(a) The substrates enter the transporter from the inner leaﬂet
and exit from the transporter into the outer leaﬂet. Substrates
could be moved from one substrate binding site to the other in
the transporter in a ‘‘ﬂip-ﬂop” way. Substrates may dissolve into
the inner leaﬂet from cytosol, and exit to an exogenous environ-
ment from the outer leaﬂet. (b) Substrates enter the transporter
from the inner leaﬂet as model (a) but exit the transporter directly
to an exogenous environment. Acceptors could be required for
the substrates to solve in an exogenous environment. Without
acceptors, the substrates would readily return to the outer leaﬂet
of the lipid bilayer. (c) Amphiphilic substrates directly enter thelsevier B.V. All rights reserved.
Fig. 1. Four processes predicted for outward lipid transport. (a) The substrates enter the transporter from the inner leaﬂet and exit from the transporter into the outer leaﬂet.
Substrates could be moved from one substrate binding site to the other in the transporter in a ‘‘ﬂip-ﬂop” way. (b) Substrates enter the transporter from the inner leaﬂet and
exit the transporter directly to an exogenous environment. (c) Amphiphilic substrates directly enter the transporter from cytosol and exit directly to an exogenous
environment. This is similar to the transport mechanisms for ions and solutes. Substrates are sometimes marked with glutathione, glucuronate, or sulfate. (d) The substrates
enter the transporter from the outer leaﬂet and exit the transporter directly to an exogenous environment. The movement of substrates in this model can be called
‘‘projection” to the exogenous environment.
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ment. This is similar to the transport mechanisms for ions and sol-
utes. (d) The substrates enter the transporter from the outer leaﬂet
and exit the transporter directly to an exogenous environment.
Acceptors would be required for the substrates to solve in an exog-
enous environment also in this case. The movement of substrates
in this model can be called ‘‘projection” to the exogenous
environment.
In this review, the mechanism of outward transmembrane lipid
transport by physiologically important human ABC proteins will be
discussed. First, ABC proteins involved in the biogenesis of the out-
er membrane in Gram-negative bacteria are described. Their trans-
port mechanisms have been studied intensively and are highly
suggestive when considering the mechanism of human ABC
proteins.
2. Bacterial ABC proteins in lipoprotein transport
The outer membrane is essential for Gram-negative bacteria,
such as Eschericia coli (E. coli). One of the major functions of the
outer membrane is a permeability barrier to hydrophobic sub-
stances. It is composed of four major components: lipopolysaccha-
ride (LPS), phospholipids, b-barrel proteins, and lipoproteins. E. coli
possesses at least 80 species of lipoproteins anchored to the peri-
plasmic face of the outer membrane thorough acyl chains attached
to their N-terminal Cys residues. Lipoproteins are synthesized as
precursors in the cytoplasm, and translocated across the inner
membrane through a Sec translocon. The precursor proteins are
then sequentially processed to the mature acylated form on the
periplasmic face of the inner membrane. Because the signal pep-
tide is processed by a signal peptidase, the mature lipoproteins
are anchored via only three acyl chains (Fig. 2a). Extensive bio-
chemical studies by Tokuda’s group [15] revealed that the outer
membrane protein LolB, the periplasmic protein LolA, and a com-
plex composed of LolC, LolD, and LolE in the inner membrane are
involved in lipoprotein transport. This LolCDE complex belongs to
the ABC transporter superfamily. LolC and LolE are membrane sub-
units, each of which spans the membrane four times, while LolD is
a nucleotide binding subunit possessing typical motifs conserved
among the ABC transporter superfamily.
The release of the lipoprotein from the inner membrane is pre-
sumed to proceed as illustrated in Fig. 2c: the lipoprotein is recog-nized by LolCDE on the periplasmic surface of the inner membrane.
Formation of the LolCDE/lipoprotein complex increases the afﬁnity
of LolD for ATP (step 1). ATP binding to LolD causes a conforma-
tional change in LolCDE and decreases the strength of the hydro-
phobic interaction between LolCDE and lipoprotein (step 2). ATP
hydrolysis presumably further weakens the hydrophobic interac-
tion of the LolCDE/lipoprotein complex, but lipoproteins remain
associated with LolCDE until LolA is added (step 3). The hydropho-
bic cavity of LolA opens on the binding of lipoproteins (step 4). Re-
lease of inorganic phosphate and ADP from LolD leads to the
original conformation of LolCDE (step 5). The process of lipoprotein
release by LolA and LolCDE does not include transmembrane
movement but occurs on one side of the membrane [16,17]. Thus,
the outward transport process mediated by LolCDE represents the
model (d) in Fig. 1, in which the substrate is ‘‘projected” from the
outer leaﬂet of the membrane.
3. Bacterial ABC proteins in LPS transport
LPS is an essential component of the outer membrane in most
Gram-negative bacteria as lipoproteins. LPS consists of a hydro-
phobic membrane anchor, lipid A moiety, linked to a short core oli-
gosaccharide and a distal long chain polysaccharide known as O-
antigen. The lipid A-core moiety is synthesized on the cytoplasmic
surface of the inner membrane and is then transported across the
inner membrane by an ABC transporter, MsbA. The movement of
the lipid A-core moiety mediated by MsbA is ‘‘ﬂip-ﬂop” from the
inner leaﬂet to the outer leaﬂet of the inner membrane [18]. Thus,
the outward transport process mediated by MsbA represents the
model (a) in Fig. 1. O-antigen is synthesized separately and is pres-
ent in its completed form at the periplasmic face of the inner mem-
brane, attached to the carrier lipid (undecaprenyl diphosphate). O-
antigen repeat units are then polymerized in the periplasm and li-
gated to the lipid A-core moiety [19].
Recently, several proteins have been identiﬁed to be involved in
LPS transport from the inner to outer membrane of E. coli [20,21].
Two transmembrane proteins, LptF and LptG, form a complex with
LptB, a cytosolic ATPase, with a subunit stoichiometry of 1:1:2, just
like LolCDE [22]. LPS is predicted to target the outer membrane
through a pathway analogous to the lipoprotein targeting system.
LptA may play a chaperone role in the transport of LPS across the
periplasm (Fig. 2b).
Fig. 2. Bacterial ABC proteins involved in lipoprotein and LPS transport. (a) Lipoprotein transport from the inner to the outer membrane. (b) LPS transport from the inner to
the outer membrane. (c) Molecular events involved in lipoprotein release from the inner membrane. Modiﬁed from Ref. [15] with permission from the publisher.
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volved in LPS transport from the inner to outer membrane. One
is MsbA, which moves lipid A-core moiety in a ‘‘ﬂip-ﬂop” manner
as does model (a), and the other is LptBFG, which possibly ‘‘pro-
jects” mature LPS to LptA, just like LolCDE as in model (d). There
may be two possible reasons why two separate systems are re-
quired for bacteria to transport LPS: (i) the two transport steps
are separated because polymerized O-antigen should be ligated
to the lipid A-core moiety on the periplasmic face of the inner
membrane after being transported by MsbA and then recognized
by LptBFG. (ii) The other reason might be that the two processes,
‘‘ﬂip-ﬂop” and ‘‘projection”, cannot be mediated by one bacterial
ABC transporter but need to be shared by two ABC transporter
systems.
4. Human ABC proteins in xenobiotic transport
In daily life, we are exposed to various hydrophobic compounds
in food and the environment that are apt to pass through the lipid
bilayer freely and penetrate our body; inconveniently, many of
them have toxic effects. Therefore, our body has to deal with
numerous hydrophobic compounds in food and the environment;
however, it is impossible to cover the intestine epithelia with cell
walls, like bacteria as described in the previous chapters, or to ex-
press a huge number of membrane transporters which excrete
each hydrophobic toxic compound with high efﬁciency. Animals
have developed mainly two strategies to cope with these hydro-
phobic substances. One strategy is that hydrophobic toxic sub-
stances are conjugated with glutathione, glucuronate, or sulfate,
whereby they become more hydrophilic and detoxiﬁed. At the
same time, these markings make toxic compounds much easier
to recognize by transporters. Several ABCC subfamily proteins
(MRPs) are involved in transporting these marked compounds
out of cells [23–27]. The marked substrates, being hydrophilic,
probably directly enter the transporter from cytosol and exit di-
rectly to an exogenous environment, as in model (c) in Fig. 1. This
pathway is very efﬁcient but has an intrinsic defect, because toxic
substances need to be taken into cells to be marked.The other strategy is to recognize numerous hydrophobic com-
pounds while passing through the plasma membrane and to ex-
crete them directly out of cells. This is accomplished mainly by
two ABC proteins MDR1 and ABCG2 [9,28]. They prevent the
absorption of lipophilic toxic compounds of various structures
from the intestine, and expels them to bile and urine from the liver
and kidney, respectively, although their binding afﬁnities are
rather low and in the micromolar range.
The substrates are predicted to enter the transporter from the
membrane. Calcein-AM, added to the medium, is efﬁciently ex-
creted by MDR1 out of cells before being hydrolyzed by esterases
in cytosol [29]. Because calcein, the hydrolyzed product, is not
the substrate for MDR1, calcein-AM must be recognized while
passing through the membrane by MDR1. It is not clear whether
substrates exit the transporter to the outer leaﬂet, as in model
(a) in Fig. 1, or directly to an exogenous environment as in model
(b); however, because lipophilic compounds readily diffuse in-
wardly again, it may be necessary to expel them directly to some
acceptors, such as albumin, in an exogenous environment for efﬁ-
cient outward transport, as in model (b).
5. ABCB4 in PC transport
Bile formation is important for cholesterol excretion from the
body as well as cholesterol absorption from the intestine, and thus
it is critical for overall cholesterol homeostasis. Several ABC pro-
teins, expressed on the apical membranes of hepatocytes, are in-
volved in the secretion of bile salts, phospholipids and
cholesterol, and thus in canalicular bile formation. ABCB4, also
called MDR3 in humans or MDR2 in mice, is essential for the secre-
tion of phosphatidylcholine (PC) into bile [10]. ABCB11, also called
a bile salt export pump or a sister of P-glycoprotein, secretes bile
salts into bile [30]. ABCG5 and ABCG8 are the main transporters
for the secretion of biliary cholesterol [31].
The function of ABCB4 is required for proper bile formation.
Mice with homozygous disruption of the Abcb4 gene show an al-
most complete absence of PC in their bile [10], which causes seg-
mental biliary strictures due to periductal ﬁbrosis, ﬁbro-
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Human ABCB4 mutations result in a wide spectrum of phenotypes,
ranging from progressive familial intrahepatic cholestasis type 3 to
adult cholestatic liver disorders, characterized by elevated c-glut-
amyl transpeptidase levels. The primary function of biliary
phospholipid excretion is to protect the membranes of cells facing
the biliary tree against bile salts via forming mixed micelles [32].
ABCB4 has an amino acid sequence with 76% identity and 86%
similarity to that of MDR1, although ABCB4 does not confer drug
resistance. Abcb4 knockout mice do not excrete any phospholipid
into bile, despite the high expression of MDR1 on the canalicular
membranes of hepatocytes. MDR1 has quite low, if any, ability to
mediate phospholipid excretion, although it actively transports an
enormously broad range of compounds to bile. ABCB4 is predicted
to transport PC from the inner to the outer leaﬂet of the canalicular
membrane in the ‘‘ﬂip-ﬂop” manner, as in model (a) in Fig. 1 and to
make PC available for extraction into the canalicular lumen by bile
salts [33–35]. ABCB4 exclusively translocates a ﬂuorescent short-
chain PC analog containing a 7-nitro-2,1,3-benzoxadiazol group
(C6-NBD-PC) [34]. Interestingly, MDR1 translocates not only C6-
NBD-PC but also C6-NBD-PE [34]. It has been reported that both
MDR1 and ABCB4 confer resistance to aureobasidin A, an antifungal
cyclic depsipeptide antibiotic, when expressed in yeast [36]. The
resistance of yeast cells to aureobasidin A conferred by ABCB4 can
be overcome by vinblastine, verapamil, and cyclosporin A. Further-
more, human ABCB4 expressed in LLC-PK1 cells mediated transepi-
thelial transport of C6-NBD-PC, digoxin, paclitaxel, daunorubicin,
vinblastine, and ivermectin, although the transport rate is low for
most drugs, and the transport is also inhibited by vinblastine,
verapamil, and cyclosporin A [37]; therefore, it is conceivable that
MDR1 and ABCB4 share conserved domains for substrate recogni-
tion and a conserved process to transport substrates, although their
physiological roles are quite different.
We reported that HEK293 cells stably expressing human ABCB4
excrete phospholipids (preferentially PC) and cholesterol when bile
salts are added to the medium [38]. Because MDR1 or the ATPase-
deﬁcient mutant of ABCB4 did not mediate lipid excretion, and no
lipid release was observed from host cells even in the presence of
bile salts, excretion of PC and cholesterol is directly mediated by
ABCB4 in an ATP-dependent manner. Abcg5/g8/ mice have
80% reduced biliary cholesterol excretion [39]. Because more
than 20% of biliary cholesterol excretion was still observed, ABCB4
might also contribute to the secretion of biliary cholesterol in some
degree. Sodium taurocholate (NaTC) below the cmc promotes
ABCB4-mediated lipid efﬂux, suggesting that bile salt monomers
support lipid efﬂux. The crystal structure of sav1866, a bacterial
homolog of ABCB1, has been reported [40]. The predicted out-
ward-facing conformation contains a central cavity that is shielded
from the inner leaﬂet of the lipid bilayer and from the cytoplasm,
but exposed to the outer leaﬂet and the extracellular space. Bile
salt monomers may associate with phospholipid and cholesterol
in the cavity of ABCB4, and then induce the formation of a mixed
bile salt/phospholipid/cholesterol micelle, which is released into
the extracellular space. The association of bile salt monomers with
phospholipid and cholesterol would reduce the activation energy
required to move substrates from the cavity of ABCB4 to the aque-
ous environment; therefore, PC, entering from the membrane, may
exit directly to an exogenous environment as in model (b), as pro-
posed for MDR1 in the previous chapter.
6. ABCA1 in HDL formation
Cholesterol is a key component of the cell membrane and is re-
quired for cell proliferation; however, excess accumulation of cho-
lesterol is toxic for cells and its excess deposition in peripheraltissues causes arteriosclerosis. Excess cholesterol is transported
to the liver, where it is catabolized to bile acids, as high density
lipoprotein (HDL) known as good cholesterol. Because cholesterol
is not catabolized in peripheral tissues, HDL formation is the only
pathway by which excess cholesterol is removed from peripheral
cells. At least 50 mutations, including 23 missense, and 21 inser-
tions or deletions, have been identiﬁed in the ABCA1 gene, leading
to Tangier disease and familial hypoalphalipoproteinemia, in
which patients have a near absence or decrease of circulating
HDL, prominent cholesterol-ester accumulation in tissue macro-
phages, and premature atherosclerotic vascular disease [41–45].
More than 15 mutations examined showed a high correlation be-
tween phospholipids, preferentially PC, and cholesterol efﬂux
[46–48], indicating that ABCA1 inﬂuences the efﬂux of both PC
and free cholesterol. ABCA1 mediates the secretion of both types
of lipids to an extracellular acceptor in the plasma, apolipoprotein
A-I (apoA-I), to form HDL [48,49], and the activity of ABCA1 is
highly regulated at the transcriptional level and also at the post-
translational level [50–56].
7. Models for ABCA1-mediated HDL formation
Several models have been proposed for the mechanism of
ABCA1-mediated HDL formation: (i) A two-step process model:
ABCA1 ﬁrst mediates PC efﬂux to apoA-I, and this apoA-I–PC com-
plex accepts cholesterol in an ABCA1-independent manner; (ii) a
concurrent process model: PC and cholesterol efﬂux by ABCA1 to
apoA-I are coupled to each other; and (iii) the third model is that
ABCA1 generates a speciﬁc apoA-I binding site on the plasma
membrane and subsequent translocation of PC and cholesterol to
apoA-I. When it was proposed by Fielding et al. [57] and Wang
et al. [58], the two-step model looked most plausible, because pho-
toactive PC could be cross-linked with ABCA1 whereas direct bind-
ing of photoactive cholesterol to ABCA1 could not be detected [58].
However, analysis of functions of ABCA7 raised questions about
this model. Human ABCA7, which has the highest homology
(66.1%) to ABCA1, mediates the apoA-I-dependent efﬂux of PC
and cholesterol, just as ABCA1 [59]; however, human ABCA7 medi-
ates cholesterol release much less efﬁciently than ABCA1 [60], and
PC but not cholesterol are loaded onto apoA-I by mouse ABCA7
[61]. These results cannot be explained by the two-step process
model. Instead, they suggest that ABCA1 have higher afﬁnity for
cholesterol to transport than ABCA7 does, and are consistent with
the concurrent process model [62].
The third model was originally proposed by Chimini and
coworkers [63]: ABCA1 mediates the translocation of phosphati-
dylserine (PS) to the outer leaﬂet, and extracellular exposure of
PS promotes apoA-I binding to the cell surface and subsequent
translocation of PC and cholesterol to apoA-I. Landry et al. [64] re-
ported that ABCA1 re-organizes the plasma membrane and gener-
ates loosely packed domains, which facilitate apoA-I association
with cells and, subsequently, PC and cholesterol acquisition by
apoA-I to form nascent HDL particles. It is still not clear what frac-
tion of lipids is directly loaded onto apoA-I by ABCA1 and what
fraction of lipids on apoA-I is indirectly acquired from membranes.
8. Four-step model for ABCA1-mediated HDL formation
Mass and TLC analyses revealed that ABCG1 and ABCA1 secrete
several species of sphingomyelin (SM) and PC, and SMs were pref-
erentially secreted by ABCG1, whereas PCs were preferentially se-
creted by ABCA1 [65]. Thus, ABCA1 and ABCB4 mediate the
transport of the same substrates, cholesterol and PC, but their
extracellular acceptors are different. ABCB4 mediates the secretion
of PC and cholesterol to bile salts as acceptors, but cannot secrete
Fig. 3. Four-step model of HDL formation mediated by ABCA1. ApoA-I binding step, ATP binding and/or hydrolysis causes conformational changes within ECDs of ABCA1, to
which apoA-I directly binds. Translocation step, lipid translocation by ABCA1, which is apoA-I-independent. Loading step, lipid loading of apoA-I bound to ABCA1.
Dissociation step, dissociation of lipid-loaded apoA-I from ABCA1. In this model, the apoA-I binding step and lipid translocation step, both of which are mediated by ABCA1 in
an ATP-dependent manner, are separable. The conformational transition of apoA-I caused by lipid loading probably facilitates the dissociation of apoA-I from ABCA1.
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secretion by ABCA1 is strongly dependent on the presence of li-
pid-free apoA-I [66,67]. ABCA1 and other members of the ABCA
subclass are distinguished from other ABC transporter subclasses
by the presence of large extracellular domains (ECDs) [68,69]
(Fig. 3). Hozoji et al. revealed that two intramolecular disulﬁde
bonds are formed between ECD1 and ECD2 of ABCA1, and these
two disulﬁde bonds are necessary for apoA-I binding and HDL for-
mation [70]. Direct interaction between ABCA1 and apoA-I has
been shown via cross-linking experiments [46,66,67,71], even with
a cross-linker as small as 3 Å [72]. These results indicated that the
direct binding of apoA-I to ABCA1 is an essential step in HDL
formation.
To analyze the differences between ABCA1 and ABCB4, we
examined whether NaTC serves as an acceptor for lipids secreted
by ABCA1, and surprisingly found that NaTC extracts both choles-
terol and PC as efﬁciently as apoA-I from cells expressing ABCA1
[73]. NaTC did not extract lipids from HEK293 host cells, suggest-
ing that NaTC functions as a lipid acceptor for ABCA1, which mim-
ics apoA-I. The NaTC-dependent efﬂux of cholesterol and PC is not
physiologically relevant, because it is unlikely that the plasma con-
centration of bile acids reaches 1 mM; however, this system al-
lowed us to analyze the role of apoA-I and dissect the steps in
HDL formation.
Because apoA-I does not bind to cells expressing ABCA1-MM, a
mutant in which the Walker A lysines in both nucleotide bindingdomains are substituted by methionines, apoA-I binding is an
ATP-dependent process [73,74]. The Tangier mutation W590S,
one amino acid substitution in the ﬁrst ECD, impairs HDL forma-
tion [46,48]. We analyzed the function of this Tangier mutant in
detail, and found that this mutation greatly decreases NaTC-depen-
dent cholesterol and PC efﬂux [73]. ABCA1–W590S interacts in a
normal manner with ATP [48]. The W590S mutation may abolish
the coupling of ATP-induced conformational changes of ABCA1 to
lipid translocation. Interestingly, the kinetics of apoA-I binding to
cells expressing ABCA1–W590S were similar to those for cells
expressing wild-type ABCA1 [73], consistent with a previous report
showing that the W590S mutation does not impair apoA-I binding
[46,47,71,75]; however, the W590S mutation delayed the dissocia-
tion of apoA-I from ABCA1 [73].
From these results, we propose that HDL formation mediated by
ABCA1 consists of at least four separate steps (Fig. 3): apoA-I bind-
ing step, ATP binding and/or hydrolysis causes conformational
changes within ECDs of ABCA1, to which apoA-I directly binds;
translocation step, lipid translocation by ABCA1, which is apoA-
I-independent; loading step, lipid loading of apoA-I bound to
ABCA1; and dissociation step, dissociation of lipid-loaded apoA-I
from ABCA1. In this model, the apoA-I binding step and lipid trans-
location step, both of which are mediated by ABCA1 in an ATP-
dependent manner, are separable. The conformational transition
of apoA-I caused by lipid loading probably facilitates the dissocia-
tion of apoA-I from ABCA1. ApoA-I undergoes a conformational
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interact with ABCA1 [66,77]. Because the W590S mutation impairs
translocation step, apoA-I may remain in lipid-free conformation,
which has high afﬁnity to ABCA1.9. Flip-ﬂop, efﬂux, or projection
As described in the previous chapter, both ABCA1 and ABCB4
mediate the efﬂux of PC and cholesterol to NaTC as a lipid acceptor
in an ATP-dependent manner; therefore, it is conceivable to predict
that they share conserved domains for substrate recognition and
conserved process to transport substrates. PC and cholesterol,
entering from the membrane, may exit directly to an exogenous
environment as in model (b), as proposed for MDR1 and ABCB4.
ABCG1, half-type ABC proteins, functions as a homodimer and
transports cholesterol to nascent HDL to generate mature HDL.
ABCG1 mediates the efﬂux of cholesterol and phospholipids, pref-
erentially SM [65]. The ABCG1-mediated efﬂux of cholesterol and
SM is dependent on the cellular SM level, because lipid efﬂux by
ABCG1 was reduced in a mutant CHO-K1 cell line, LY-A, in which
the cellular sphingomyelin level is reduced due to a mutation of
ceramide transfer protein CERT [78]. In contrast, the ABCA1-medi-
ated efﬂux of cholesterol and PC is enhanced in LY-A cells [79].
These results indicate that the substrate speciﬁcity of ABCA1 and
ABCG1 is different; ABCA1 prefers PC and ABCG1 prefers sphingo-
myelin. Alternatively, it is possible that ABCA1 preferentially func-
tions in non-raft domains, which contain more PC than SM, and
ABCG1 preferentially functions in raft domains, where SM is con-
centrated, in the plasma membrane.
As SM is synthesized in the lumen of trans-Golgi, and trans-
ferred by vesicular transport, SM mainly exists in the outer leaﬂet.
Substrate binding sites of ABCG1 could exist in the outer leaﬂet,
and lipids could enter the binding site mainly from the outer leaﬂet
of the plasma membrane. If this is the case, the outward transport
process mediated by ABCG1 would follow model (d) in Fig. 1, in
which the substrate is ‘‘projected” from the outer leaﬂet of the
membrane without transmembrane movement, as LolCDE. PC also
preferentially exists in the outer leaﬂet of the plasma membrane.
Does this suggest that the outward transport process mediated
by ABCA1 follows the model (d), as predicted for LolCDE? The
four-step model for HDL formation mediated by ABCA1 and
apoA-I (Fig. 3) looks similar to the model for the release of the lipo-
protein from the inner membrane mediated by LolCDE and LolA
(Fig. 2c). Both apoA-I and LolA directly bind to ABCA1 and LolCDE,
respectively. Both ABCA1 and LolCDE move the substrate even in
the absence of apoA-I or LolA and load substrates to their acceptors
in an ATP-dependent manner. The main difference between the
functions of ABCA1 and LolCDE is that the produced nascent HDL
consists of more than 200 lipid molecules and two apoA-I proteins,
while the LolA/lipoprotein complex in the periplasm consists of
one lipoprotein molecule and one LolA protein. Further studies
are needed to reveal the mechanism of HDL formation by ABCA1.
From a mechanistic aspect, the alternative access model is gen-
erally accepted for the mechanism of most transport; however, the
following mechanism may be more appropriate for the projection-
type transporter; lipophilic substrates enter the binding site of the
transporter from membranes. Conformational change, as in the
motion of TM a-helix bundles, caused by ATP binding or hydrolysis
makes the binding sites hydrophilic, which facilitates the dissocia-
tion of substrates from the binding site to the external environ-
ment or directly to the acceptor. The substrates might enter the
binding site of the transporter either from the outer or inner leaﬂet
of membranes. Does outward transport by the multi-drug trans-
porter MDR1, highly homologous to ABCB4, also follow this pro-
cess? We may be able to uncover this mystery by comparingMDR1, ABCB4, ABCA1, and other ABC proteins. 3D-structural anal-
yses of eukaryote drug-transporting and lipid-transporting ABC
proteins are required.
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